HR 4299 · 113th Congress 2013โ€“2015, ended

Improving Regulatory Transparency for New Medical Therapies Act

Latest action · Sep 19, 2014 Placed on the Union Calendar, Calendar No. 451.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMar 26, 2014
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Improving Regulatory Transparency for New Medical Therapies Act - Amends the Controlled Substances Act to require any proceedings for the issuance, amendment, or repeal of a rule of the Attorney General for the classification of a controlled substance that are initiated at the request of the Secretary of Health and Human Services (HHS) to control a drug or other substance not previously scheduled, where the Secretary has recommended the drug or other substance be placed in schedule II, III, IV, or V, to be commenced not later than 120 days after receipt of written recommendations from the Secretary. Requires the final rule to be issued not later than 60 days after the date on which both the public comment period has closed and the new drug is the subject of an approved new drug application, unless a hearing on the proposed rule is granted by the Attorney General.

Directs the Attorney General, for the purposes of registration to manufacture a controlled substance in schedule III, IV, or V for use only in a clinical trial, to register an applicant, or serve upon the applicant an order to show cause why registration should not be denied, revoked, or suspended, not later than 180 days after receiving an application and all information necessary to make a determination about whether the issuance of such registration is inconsistent with the public interest.

Directs the Attorney General, for the purposes of registration to manufacture a controlled substance in schedule I or II for use only in a clinical trial, to: (1) issue a notice of application not later than 90 days after receipt of an application and all necessary information to issue such notice; and (2) register an applicant, or serve upon the applicant an order to show cause why registration should not be denied, revoked, or suspended, within 180 days following the close of the comment period and receipt of all information necessary to make a determination about whether the issuance of such registration is consistent with the public interest and with U.S. obligations under international treaties in effect on May 1, 1971, unless a hearing on the application has been granted pursuant to a provision of the Controlled Substances Import and Export Act regarding emergency situations.

Cosponsors 15

Members who signed on, in the order they did. Signatures ran from Mar 26, 2014 to Sep 8, 2014; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-NJFrank Pallone, Jr.OriginalMar 26, 2014
R-TXMichael C. BurgessApr 1, 2014
R-WACathy McMorris RodgersApr 3, 2014
R-TNMarsha BlackburnApr 8, 2014
R-VAH. Morgan GriffithApr 9, 2014
R-GAPhil GingreyApr 9, 2014
D-TXGene GreenApr 10, 2014
R-OHRobert E. LattaApr 29, 2014
D-NHCarol Shea-PorterMay 19, 2014
D-NYEliot L. EngelMay 19, 2014
D-NCG. K. ButterfieldMay 20, 2014
D-NYPaul TonkoMay 28, 2014
R-OHBill JohnsonMay 29, 2014
R-GADoug CollinsSep 8, 2014
R-MSGregg HarperSep 8, 2014

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Mar 26, 2014Markup Jun 10, 2014Reported Jul 29, 2014
Health Subcommittee
Referred Mar 28, 2014Markup May 28, 2014Reported May 28, 2014
HouseJudiciary Committee
Referred Mar 26, 2014Markup Sep 10, 2014Reported Sep 19, 2014
Crime and Federal Government Surveillance Subcommittee
Referred Apr 16, 2014Discharged Sep 9, 2014

Actions 16

Everything that happened, newest first.

  1. Sep 19, 2014Reported (Amended) by the Committee on Judiciary. H. Rept. 113-565, Part II.
  2. Sep 19, 2014Placed on the Union Calendar, Calendar No. 451.
  3. Sep 10, 2014Committee Consideration and Mark-up Session Held.
  4. Sep 10, 2014Ordered to be Reported (Amended) by Voice Vote.
  5. Sep 9, 2014Subcommittee on Crime, Terrorism, Homeland Security, and Investigations Discharged.
  6. Jul 29, 2014Reported by the Committee on Energy and Commerce. H. Rept. 113-565, Part I.
  7. Jul 29, 2014House Committee on the Judiciary Granted an extension for further consideration ending not later than Sept. 19, 2014.
  8. Jun 10, 2014Committee Consideration and Mark-up Session Held.
  9. Jun 10, 2014Ordered to be Reported by Voice Vote.
  10. Jun 9, 2014Committee Consideration and Mark-up Session Held.
  11. May 28, 2014Subcommittee Consideration and Mark-up Session Held.
  12. May 28, 2014Forwarded by Subcommittee to Full Committee by Voice Vote .
  13. Apr 16, 2014Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
  14. Mar 28, 2014Referred to the Subcommittee on Health.
  15. Mar 26, 2014Introduced in House
  16. Mar 26, 2014Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Congressional Budget Office cost estimates 2

  1. Sep 25, 2014H.R. 4299, Improving Regulatory Transparency for New Medical Therapies ActAs ordered reported by the House Committee on the Judiciary on September 10, 2014
  2. Jun 27, 2014H.R. 4299, Improving Regulatory Transparency for New Medical Therapies ActAs ordered reported by the House Committee on Energy and Commerce on June 10, 2014

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article I, Section 8, Clause 3, which states that Congress shall have the power ``to regulate commerce with foreign nations, and among the several states. . .''

The sponsor’s statement, as printed in the page H2695.

Printed hearings 2

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
Serial No. 113-109DRUG ENFORCEMENT ADMINISTRATION59 pagesJudiciary CommitteeSep 18, 2014
Serial No. 113-137IMPROVING PREDICTABILITY AND TRANSPARENCY IN DEA AND FDA REGULATION221 pagesEnergy and Commerce CommitteeApr 7, 2014

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 2862Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014Related billSep 18, 2014

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.
Short Titles as Introduced
Improving Regulatory Transparency for New Medical Therapies Act
Short Titles as Reported to House
Improving Regulatory Transparency for New Medical Therapies Act

Subjects

Assigned by the Library of Congress. Policy area: Crime and Law Enforcement.

Text 2

Each version as it was printed, newest first.

  1. Sep 19, 2014Reported in House
  2. Mar 26, 2014Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.